Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Jennifer L. Leiting

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5784-7937; OpenAlex author ID A5013823935. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
66
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 7

  1. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  2. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  3. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  4. In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts. Co-author DOI 10.1038/s42003-023-05368-y↗
  5. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  6. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinica… Co-author DOI 10.1016/j.jamcollsurg.2021.05.009↗
  7. Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftmen… Co-author DOI 10.1016/j.tranon.2018.09.008↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark Joseph Truty · 7 shared papers, 2019–2026 · strength 1.06
  2. Michael L. Kendrick · 5 shared papers, 2021–2026 · strength 0.80
  3. Cornelius A. Thiels · 4 shared papers, 2022–2026 · strength 0.68
  4. Amro M. Abdelrahman · 4 shared papers, 2021–2025 · strength 0.59
  5. Jennifer A. Yonkus · 4 shared papers, 2021–2025 · strength 0.59
  6. Sean Patrick Cleary · 3 shared papers, 2021–2025 · strength 0.44
  7. Travis Edward Grotz · 3 shared papers, 2021–2025 · strength 0.44
  8. Roberto Alva‐Ruiz · 3 shared papers, 2021–2025 · strength 0.44
  9. Freek D. Daams · 2 shared papers, 2026 · strength 0.37
  10. Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.37
  11. Oskar Franklin · 2 shared papers, 2026 · strength 0.37
  12. Patrik Larsson · 2 shared papers, 2026 · strength 0.37
  13. Ernesto Sparrelid · 2 shared papers, 2026 · strength 0.37
  14. Bas Groot Koerkamp · 2 shared papers, 2026 · strength 0.37
  15. Poya Ghorbani · 2 shared papers, 2026 · strength 0.37
  16. Thomas F. Stoop · 2 shared papers, 2026 · strength 0.37
  17. Hiroyuki Ishida · 2 shared papers, 2026 · strength 0.37
  18. Roeland F. de Wilde · 2 shared papers, 2026 · strength 0.37
  19. Christopher Lee Wolfgang · 2 shared papers, 2026 · strength 0.37
  20. Marc G. Besselink · 2 shared papers, 2026 · strength 0.37
  21. Marco Del Chiaro · 2 shared papers, 2026 · strength 0.37
  22. Geert Kazemier M · 2 shared papers, 2026 · strength 0.37
  23. Richard David Schulick · 2 shared papers, 2026 · strength 0.37
  24. Ammar A. Javed · 2 shared papers, 2026 · strength 0.37
  25. Susanne Gray Warner · 2 shared papers, 2022–2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.